Integrated service partners outperform standalone CDMOs in clinical development – Thermo Fisher
Engaging an integrated services partner could reduce risk and speed-up the process for drug sponsors.
Drug product development can be an expensive and time-consuming process, with development companies facing a range of challenges in their efforts to create a scalable, marketable formulation, ensure safety and efficacy of the drug product, and ultimately receive regulatory approval.
Partnerships between Contract Development and Manufacturing Organisations (CDMOs) and drug sponsors offer significant benefits, though collaborating with a range of different vendors incurs its own set of risks.
This was the subject of a presentation by Kevin Kane, Senior Staff Scientist, R&D at Thermo Fisher, during CPHI North America last week. Kane offered insights into the sponsor’s clinical development journey and discussed de-risking CMC (Chemistry, Manufacturing and Controls) services offered by CDMOs.
Kane noted that large pharmaceutical companies are looking for ‘specialty capabilities they might not have in-house' or ‘flex capacity because they’re busy with other things’ when engaging a CDMO partner, while smaller biotechs are ‘really looking for everything.’
Speaking about smaller companies, he said: ‘They’re focused on the disease state. They don’t have the time to build out capabilities, so they’re looking for partners that will help them move downstream and leverage the expertise that comes from working with different molecules over the years.’
Kane added that both small and large companies are seeking ‘the best return now’ from CDMO relationships.
It is common for sponsors to engage multiple vendors when attempting to bring a drug to market, which Kane refers to as ‘brute force development’. This approach requires considerable effort and resources from the sponsor, who must negotiate and oversee multiple service and quality agreements.
Vendors tend to take responsibility for their own work, not the overall success of the programme, and it can be difficult to mitigate delays when the process is so fragmented. As there is no single point of accountability on the vendor's side, the sponsor incurs almost all of the risk.
Kane advises engaging an integrated services partner to de-risk CMC programmes.
Integrated services
Taking an integrated services approach can have many benefits for drug sponsors, including closer alignment to clinical needs, seamless handoff between sites, and cost savings.
He said: ‘What we want is to reduce the time where the client’s sat waiting around, because their overhead costs are running. So, any time we can take weeks or months off their overall timeline where they’re having to wait for the next step, that’s the benefit of an integrated services offering.’
Kane advised evaluating everything an integrated services partner has to offer and deciding which services best suit the needs of the project. He also encouraged sponsors to share their clinical strategy with CMC partners and to view these sponsors as ‘potential collaborators’.
API development strategies
It is critical for sponsors to be able to account for the manufacturing needs and challenges of APIs and develop a sound strategy for producing drugs efficiency, consistently and cost-effectively.
Kane advises that sponsors evaluate their approach to API development, noting that early investment in development can ‘yield downstream dividends in API progression’.
This can allow companies to make smarter selections in terms of regulatory starting materials, create a process that avoids overly hazardous reagents, and make earlier decisions on final isolation solvents.
He also noted the benefits of identifying API solubility issues early in the process, saying this ‘allows us to predict and shave off weeks of potential dead-end experimental work’.
Service offering
Kane then touched on Thermo Fisher’s solid-state chemistry services, continuous manufacturing programme, and Quick to Care™ solution. He advised sponsors to ‘flip the script’ to get the best returns from CMC partners and advised tackling clinical objectives and requirements early in the relationship.
‘Clients, help us understand what your clinical objectives are. Make sure we’re lined up with that. If we’re not listening, knock us on the head,’ he concluded.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance